AC   CVCL_1119
SY   CFPac-1; CF PAC-1; CF-PAC1; CF-Pac1; CF Pac1; CFPAC1; CFPac1; CFPAC
DR   BTO; BTO:0004738
DR   CLO; CLO_0002395
DR   EFO; EFO_0006551
DR   CLDB; cl705
DR   CLDB; cl7121
DR   ATCC; CRL-1918
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471976
DR   BioSample; SAMN10987887
DR   CCRID; 1101HUM-PUMC000245
DR   CCRID; 3101HUMTCHu112
DR   CCRID; 4201HUM-CCTCC00249
DR   Cell_Model_Passport; SIDM00130
DR   CGH-DB; 164-1
DR   CGH-DB; 9273-4
DR   ChEMBL-Cells; CHEMBL3308032
DR   ChEMBL-Targets; CHEMBL613506
DR   CLS; 305066
DR   Cosmic; 710854
DR   Cosmic; 868245
DR   Cosmic; 872998
DR   Cosmic; 906821
DR   Cosmic; 913305
DR   Cosmic; 922259
DR   Cosmic; 923168
DR   Cosmic; 932518
DR   Cosmic; 948375
DR   Cosmic; 948741
DR   Cosmic; 949322
DR   Cosmic; 1006363
DR   Cosmic; 1122343
DR   Cosmic; 1198207
DR   Cosmic; 1299298
DR   Cosmic; 1358477
DR   Cosmic; 1518233
DR   Cosmic; 1571776
DR   Cosmic; 2434110
DR   Cosmic-CLP; 906821
DR   DepMap; ACH-000138
DR   ECACC; 91112501
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 906821
DR   GEO; GSM206454
DR   GEO; GSM244428
DR   GEO; GSM621903
DR   GEO; GSM784694
DR   GEO; GSM886925
DR   GEO; GSM887991
DR   GEO; GSM1024400
DR   GEO; GSM1374446
DR   GEO; GSM1374447
DR   GEO; GSM1374448
DR   GEO; GSM1669672
DR   IARC_TP53; 2839
DR   ICLC; HTL01019
DR   KCB; KCB 200730YJ
DR   LiGeA; CCLE_601
DR   PharmacoDB; CFPAC1_193_2019
DR   PRIDE; PXD003198
DR   PRIDE; PXD030304
DR   PRIDE; PXD032263
DR   Progenetix; CVCL_1119
DR   PubChem_Cell_line; CVCL_1119
DR   Wikidata; Q28199352
RX   DOI=10.4172/2324-9293.1000104;
RX   DOI=10.4172/jpb.1000057;
RX   PubMed=1692630;
RX   PubMed=10027410;
RX   PubMed=10408907;
RX   PubMed=11169959;
RX   PubMed=11787853;
RX   PubMed=12800145;
RX   PubMed=14695172;
RX   PubMed=15126341;
RX   PubMed=15367885;
RX   PubMed=15463957;
RX   PubMed=15688027;
RX   PubMed=16912165;
RX   PubMed=18380791;
RX   PubMed=19077451;
RX   PubMed=20164919;
RX   PubMed=20418756;
RX   PubMed=22460905;
RX   PubMed=22585861;
RX   PubMed=25167228;
RX   PubMed=25485619;
RX   PubMed=25984343;
RX   PubMed=26216984;
RX   PubMed=26589293;
RX   PubMed=27259358;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI RAS program mutant KRAS cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 30 hours (Note=At 17th passage), 32 hours (Note=At 74th passage) (PubMed=1692630); 45 hours (PubMed=25984343).
CC   HLA typing: A*02:01,03:01; B*35:08,73:01; C*04:01,15:05 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=10408907; PubMed=11169959; PubMed=11787853; PubMed=15367885; PubMed=18380791).
CC   Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=15463957; ATCC).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=11169959; PubMed=11787853; PubMed=15367885; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Arg (c.724T>C); ClinVar=VCV000449512; Zygosity=Homozygous (PubMed=11169959; PubMed=11787853; PubMed=15367885; Cosmic-CLP).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=3.95%; Native American=0%; East Asian, North=5.48%; East Asian, South=0%; South Asian=0%; European, North=45.39%; European, South=45.18% (PubMed=30894373).
CC   Misspelling: CFPANC1; CGH-DB=164-1.
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
ST   Source(s): ATCC; CCRID; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D12S391: 17
ST   D13S317: 12
ST   D16S539: 9,11
ST   D18S51: 12
ST   D19S433: 13,15
ST   D21S11: 30,31.2
ST   D2S1338: 18,23
ST   D2S441: 10,14
ST   D3S1358: 16
ST   D5S818: 10,11
ST   D6S1043: 20
ST   D7S820: 8,10
ST   D8S1179: 11,15
ST   FGA: 21,22
ST   Penta D: 11,13
ST   Penta E: 10,12
ST   TH01: 8
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C2975; Cystic fibrosis
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
DI   ORDO; Orphanet_586; Cystic fibrosis
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   26Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 43
RX   DOI=10.4172/2324-9293.1000104;
RA   Wagenhauser M.U., Ruckert F., Niedergethmann M., Grutzmann R.,
RA   Saeger H.-D.;
RT   "Distribution of characteristic mutations in native ductal
RT   adenocarcinoma of the pancreas and pancreatic cancer cell lines.";
RL   Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013).
RX   DOI=10.4172/jpb.1000057;
RA   Masayo Y., Kiyonaga F., Koji K., Setsuo H., Tadashi K.;
RT   "The proteomic profile of pancreatic cancer cell lines corresponding
RT   to carcinogenesis and metastasis.";
RL   J. Proteomics Bioinformatics 2:1-18(2009).
RX   PubMed=1692630; DOI=10.1073/pnas.87.10.4012;
RA   Schoumacher R.A., Ram J., Iannuzzi M.C., Bradbury N.A., Wallace R.W.,
RA   Hon C.T., Kelly D.R., Schmid S.M., Gelder F.B., Rado T.A.,
RA   Frizzell R.A.;
RT   "A cystic fibrosis pancreatic adenocarcinoma cell line.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4012-4016(1990).
RX   PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4;
RA   Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A.,
RA   Meltzer P.S., Ried T.;
RT   "Specific chromosomal aberrations and amplification of the AIB1
RT   nuclear receptor coactivator gene in pancreatic carcinomas.";
RL   Am. J. Pathol. 154:525-536(1999).
RX   PubMed=10408907; DOI=10.1016/S0304-3835(98)00380-2;
RA   Bartsch D.K., Barth P., Bastian D., Ramaswamy A., Gerdes B.,
RA   Chaloupka B., Deiss Y., Simon B., Schudy A.;
RT   "Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell
RT   lines than in primary pancreatic adenocarcinomas.";
RL   Cancer Lett. 139:43-49(1999).
RX   PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C;
RA   Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M.,
RA   Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.;
RT   "Non-random chromosomal rearrangements in pancreatic cancer cell lines
RT   identified by spectral karyotyping.";
RL   Int. J. Cancer 91:350-358(2001).
RX   PubMed=11787853; DOI=10.1007/s004280100474;
RA   Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R.,
RA   Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H.,
RA   Lohr J.-M., Scarpa A.;
RT   "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras,
RT   p53, p16 and DPC4/Smad4.";
RL   Virchows Arch. 439:798-802(2001).
RX   PubMed=12800145; DOI=10.1002/gcc.10218;
RA   Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B.,
RA   Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A.,
RA   Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D.,
RA   Edwards P.A.W., Chaffanet M.;
RT   "A recurrent chromosome translocation breakpoint in breast and
RT   pancreatic cancer cell lines targets the neuregulin/NRG1 gene.";
RL   Genes Chromosomes Cancer 37:333-345(2003).
RX   PubMed=14695172;
RA   Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V.,
RA   Shen-Ong G.L., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J.,
RA   Kern S.E., Goggins M.G., Hruban R.H.;
RT   "Highly expressed genes in pancreatic ductal adenocarcinomas: a
RT   comprehensive characterization and comparison of the transcription
RT   profiles obtained from three major technologies.";
RL   Cancer Res. 63:8614-8622(2003).
RX   PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159;
RA   Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L.,
RA   Veltman J.A., van Kessel A.G., Hoglund M.;
RT   "Genome-wide array-based comparative genomic hybridization reveals
RT   multiple amplification targets and novel homozygous deletions in
RT   pancreatic carcinoma cell lines.";
RL   Cancer Res. 64:3052-3059(2004).
RX   PubMed=15367885; DOI=10.1097/00006676-200410000-00004;
RA   Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M.,
RA   Hirohashi S.;
RT   "Orthotopic transplantation models of pancreatic adenocarcinoma
RT   derived from cell lines and primary tumors and displaying varying
RT   metastatic activity.";
RL   Pancreas 29:193-203(2004).
RX   PubMed=15463957; DOI=10.1016/j.jcf.2004.05.040;
RA   Gruenert D.C., Willems M., Cassiman J.-J., Frizzell R.A.;
RT   "Established cell lines used in cystic fibrosis research.";
RL   J. Cyst. Fibros. 3:191-196(2004).
RX   PubMed=15688027; DOI=10.1038/sj.onc.1208383;
RA   Heidenblad M., Lindgren D., Veltman J.A., Jonson T., Mahlamaki E.H.,
RA   Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.;
RT   "Microarray analyses reveal strong influence of DNA copy number
RT   alterations on the transcriptional patterns in pancreatic cancer:
RT   implications for the interpretation of genomic amplifications.";
RL   Oncogene 24:1794-1801(2005).
RX   PubMed=16912165; DOI=10.1158/0008-5472.CAN-06-0721;
RA   Calhoun E.S., Hucl T., Gallmeier E., West K.M., Arking D.E.,
RA   Maitra A., Iacobuzio-Donahue C.A., Chakravarti A., Hruban R.H.,
RA   Kern S.E.;
RT   "Identifying allelic loss and homozygous deletions in pancreatic
RT   cancer without matched normals using high-density single-nucleotide
RT   polymorphism arrays.";
RL   Cancer Res. 66:7920-7928(2006).
RX   PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x;
RA   Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A.,
RA   Shiratori K., Hirohashi S., Inazawa J., Imoto I.;
RT   "Identification of SMURF1 as a possible target for 7q21.3-22.1
RT   amplification detected in a pancreatic cancer cell line by in-house
RT   array-based comparative genomic hybridization.";
RL   Cancer Sci. 99:986-994(2008).
RX   PubMed=19077451; DOI=10.1159/000178871;
RA   Harada T., Chelala C., Crnogorac-Jurcevic T., Lemoine N.R.;
RT   "Genome-wide analysis of pancreatic cancer using microarray-based
RT   techniques.";
RL   Pancreatology 9:13-24(2009).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963;
RA   Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J.,
RA   Scaife C.L., Firpo M.A., Mulvihill S.J.;
RT   "Phenotype and genotype of pancreatic cancer cell lines.";
RL   Pancreas 39:425-435(2010).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
RX   PubMed=25167228; DOI=10.1038/bjc.2014.475;
RA   Hamidi H., Lu M., Chau K., Anderson L., Fejzo M., Ginther C.,
RA   Linnartz R., Zubel A., Slamon D.J., Finn R.S.;
RT   "KRAS mutational subtype and copy number predict in vitro response of
RT   human pancreatic cancer cell lines to MEK inhibition.";
RL   Br. J. Cancer 111:1788-1801(2014).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
RX   PubMed=26216984; DOI=10.1073/pnas.1501605112;
RA   Daemen A., Peterson D., Sahu N., McCord R., Du X.-N., Liu B.,
RA   Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R.,
RA   Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.L.,
RA   Manning G., Settleman J., Hatzivassiliou G., Evangelista M.;
RT   "Metabolite profiling stratifies pancreatic ductal adenocarcinomas
RT   into subtypes with distinct sensitivities to metabolic inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=27259358; DOI=10.1074/mcp.M116.058313;
RA   Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M.,
RA   Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K.,
RA   Biankin A.V., Wu J., Daly R.J.;
RT   "Resolution of novel pancreatic ductal adenocarcinoma subtypes by
RT   global phosphotyrosine profiling.";
RL   Mol. Cell. Proteomics 15:2671-2685(2016).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).